Zanubrutinib (BRUKINSA), approved by FDA in November 2019, used in the treatment of adult patients with mantle cell lymphoma (MCL), a form of blood cancer. It is an inhibitor of Bruton’s tyrosine kinase (BTK). Part of this molecule is a fused pyrazolopyrimidine cycle. We have created a set of Building Blocks, which contain this heterocycle, to generate new ideas for your projects: